21394-91-2

Upstream product

• 103-84-4 Acetanilid 
• 64-19-7 acetic acid 
• 21282-90-6 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone 
• 5473-15-4 4-(4-acetamidophenyl)-4-oxobutanoic acid 

Downstream Products

• 95641-07-9 6-p-acetamidophenyl-4-benzylpyridazin-3(2H)-one 
• 221048-78-8 N-{4-[5-(4-methoxy-benzyl)-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-acetamide 
• 52241-06-2 6-(4-aminophenyl)-2-methyl-4,5-dihydropyridazine-3(2H)-one 
• 21282-90-6 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone 
• 221048-85-7 6-p-acetamidophenyl-4-benzoyl-2(2'-cyanoethyl)pyridazine-3(2H)-one 
• 221048-88-0 N-{4-[5-(4-methoxy-benzoyl)-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-acetamide 
• 221048-98-2 6-p-acetamidophenyl-4-benzoyl-3-chloropyridazine 
• 221048-87-9 6-p-acetamidophenyl-4-benzoylpyridazin-3(2H)-one 
• 221048-83-5 N-[4-(5-benzyl-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-phenyl]-acetamide 

Relevant academic research and scientific papers

Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators

Using computational bioactivity prediction models we identified phosphodiesterase 3B (PDE3B) and cathepsin L as macromolecular targets of de novo designed compounds. By disclosing the most potent cathepsin L activator known to date, small molecule repurposing by target panel prediction represents a feasible route towards innovative leads for chemical biology and molecular medicine. This journal is

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities

This paper reports on the synthesis and pharmacological activity of 6-aryl-4,5-dihydro-3(2H)-pyridazinone derivatives. The compounds exhibit an aggregation inhibiting action on human platelets in vitro and on rat platelets under ex vivo conditions, as wel

Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents

Substituted 6-phenyl-3(2H)-pyridazinone compounds are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted γ-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 6-phenyl-4,5-dihydro-3(2H)-pyridazinones which are dehydrogenated to the desired product. The intermediate 6-phenyl-4,5-dihydro-3(2H)-pyridazinones are themselves useful as cardiotonic agents.